Roche Completes Acquisition of BioVeris

Roche Diagnostics is free to expand its immunochemistry business into new market segments

Roche Diagnostics today announces that it has completed its acquisition of BioVeris. Roche signed the merger agreement with BioVeris for approximately $600 million on April 4, 2007.  This means Roche Diagnostics now owns the patents for Electrochemiluminescence (ECL) technology and can expand its immunochemistry business from the human diagnostics field into new market segments such as life sciences research, life science development, patient self-testing, veterinary testing, drug discovery, drug development and clinical trials.

“We are excited to be able to offer ECL technology to existing and new customers for these expanded uses. This is a highly innovative technology that our customers and their patients will certainly benefit from,” said Andy Thomson, Senior Vice President, Centralized Diagnostics, Roche Diagnostics Corporation.

Today, Roche is a leader in immunochemistry, driven by its highly successful Elecsys® immunochemistry product line, the fastest growing portfolio of Roche Diagnostics’ lab diagnostics business.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. For further information, please visit our websites at www.roche-diagnostics.us and www.roche.com.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Doyia Turner

Corporate Communications

Phone: 317-521-7252

Cell: 317-694-0335

e.mail: doyia.turner@roche.com